drugset / Trial / NCT03825731
A Study of GC022 CAR-T Cell Immunotherapy for Relapsed or Refractory B- ALL
NaSingle-groupOpen-labelTreatment
Summary
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of GC022 CAR-T cell immunotherapy in relapsed or refractory B-ALL. The investigators plan to include 20 subjects to receive GC022 therapy.
Timeline
- Start
- 2019-01-17
- Primary completion
- 2019-09-16
- Completion
- 2019-09-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC022 | Cell therapy | 300000 cells/kg | — |
| Subject | GC022 | Cell therapy | 1e+07 cells/kg | — |